The influence of chloroquine on the formation of porphyrins by yeasts

Kotal, P; Vernerová, J.; Jirsa, M; Kordač, V

doi:10.1016/0020-711x(84)90093-4

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially chloroquine phosphate (250 mg) was used; however, because of the lack of availability, currently we use hydroxychloroquine sulfate (400 mg) as the equivalency between both drugs was established as 4 mg/kg/dose of chloroquine ≈ 6 mg/kg/dose of hydroxychloroquine . Several hypotheses explain antimalarial mechanism of action: (i) It forms complexes with porphyrins, removing them from hepatocytes by exocytosis and increasing excretion of urinary porphyrins; (ii) Reduces intracellular concentration of porphyrins by increasing vacuolar cell membrane permeability; (iii) Reduces the activity of ALA‐synthase, which is increased in PCT; and (iv) Restores hepatic UROD activity removing hepatic iron . Patients treated with antimalarial showed a significant reduction of ferritin in our study.…”

Section: Discussionmentioning

confidence: 99%

Experience in management of porphyria cutanea tarda in a tertiary referral Brazilian hospital from 2002 to 2017

2019

View full text Add to dashboard Cite

Background Porphyria cutanea tarda (PCT) is the most common porphyria worldwide.The known acquired precipitating factors that induce PCT include alcoholism, hepatitis C virus infection, human immunodeficiency virus infection, and estrogen intake. Hereditary hemochromatosis is considered an inherited risk factor. The aim of this study was to describe and analyze precipitating factors and family history, with emphasis on PCT management. Methods A retrospective study of 87 patients with PCT was conducted between January 2002 and December 2017.Results A male predominance of 1.8 : 1 was found. The median age at diagnosis was 49 years (range 18-71). Family history of PCT was observed in 19.5% of patients. Two or more acquired precipitating factors were present in 42.5%. Patients were treated with antimalarial monotherapy (72.4%), antimalarial combined with phlebotomy (22.9%), and only with phlebotomy (4.6%). Acquired precipitating factors and inherited factors were not associated with treatment group. There was a difference in 24 h-UP normalization rate between treatment groups; combined therapy takes longer than antimalarial monotherapy, 38 months versus 15 months, respectively (CI 95%, 6.5-63.5 vs. 12.9-17) (log-rank test, P = 0.004).Conclusion Precipitating factors did not seem to be associated with treatment choice; however, all acquired and inherited precipitating factors should be investigated, and the choice between phlebotomy and/or antimalarials should be individualized. All dermatologists treating PCT patients should observe transferrin saturation and ferritin levels to search for underlying hereditary hemochromatosis. * P = 0.021 according to a t-test.

show abstract